Miltenyi Biotec, TeutoCell to Advance Cell Culture Techniques

May 12, 2011

BERGISCH GLADBACH, Germany, May 12, 2011 /PRNewswire/ — Miltenyi Biotec,
the only company to offer a seamless experimental integration path from
sample preparation through cell separation, culture, and analysis for primary
cells, today entered into a strategic alliance with TeutoCell, a provider of
cutting edge cell culture technology. The new partnership will broaden that
experimental integration path to include cell culture for biomanufacturing
with the addition of five novel cell culture media. The first of these,
CHOMACS CD, a medium for the production of biopharmaceutical proteins,
becomes available as of today.

Based on TeutoCell’s cell culture medium, CHOMACS CD has been
successfully tested with 11 cell lines and clones, including CHO K1, CHO
DP-12, and CHO DHFR-. It provides a low osmolality to reach an optimal basis
for fedbatch processes, and is capable of creating cell concentrations of
1.5×107 cells/mL and beyond, depending on cell line. CHOMACS CD forms the two
companies’ base medium, and will soon be followed by a feed supplement.

“Every CHO clone reacts differently to different media, which can be a
real pain for development teams when new clones are used to produce new
biopharmaceuticals,” explains Dr. Bernd Schroder, Head of Production Upstream
Processing, Miltenyi Biotec. “CHOMACS CD is an excellent choice for a large
range of clones, which means betting on Miltenyi Biotec is likely to save
them a big headache.”

To broaden the product spectrum and create more value for their
customers, in addition to a feed medium for CHO cells, TeutoCell and Miltenyi
Biotec are currently developing specialized culture media for HEK and
Hybridoma cells. All media are chemically defined, animal component- and
protein-free, or with low protein content, facilitating downstream
purification and regulatory compliance. TeutoCell’s media development and
optimization methodologies involve parallel cultivation and data modeling for
the most rational, effective, and customer-centric design of cell culture

“TeutoCell is committed to continually improving cell culture technology,
while Miltenyi Biotec’s expertise in cell processing, cell analysis and GMP
production makes it an ideal partner for us to develop innovative
technologies,” concludes Stefan Northoff, CEO, TeutoCell AG.

Under the terms of the deal, Miltenyi Biotec will become the exclusive
worldwide source of CHOMACS CD for the next five years, with an option to
extend thereafter.

About Miltenyi Biotec

Miltenyi Biotec is one of the largest and most successful biotechnology
companies in Germany, with more than 1,200 employees worldwide who develop,
produce and sell products and services for biomedical research and clinical
applications. Established in 1989, the company is still owned and run by its
founder, Stefan Miltenyi, creator of the renowned MACS(R) Technology for
magnetic separation of cells. MACS Technology has become the de facto
industry gold standard in cell separation in research laboratories worldwide,
while the name of Miltenyi Biotec has become synonymous with basic,
translational, and clinical research in cellular therapy applications.

About TeutoCell AG

Founded in 2009 by internationally renowned experts, TeutoCell AG
provides superior solutions for pharmaceutical industry and academic
institutions in the field of mammalian cell-based cultivation processes.
TeutoCell has developed a range of ultrahigh performance, chemically defined,
and animal component-free culture media for different types of production
cell lines (including CHO, hybridoma, and HEK), meeting all necessary quality
standards required by the regulatory authorities for GMP manufacturing
processes by the regulatory authorities. Based on proprietary metabolic
models and powerful analytical tools, and using its superior platform
technology, TeutoCell offers targeted, rapid, and efficient services for
development and optimization of specialized culture media for customers
production cell lines. Extensive process and protein product analytics
including extra- and intracellular substrate and metabolite quantification
and protein glycosylation analysis complete TeutoCell’s position as
innovative product and service provider for cell culture technology.

    For further information, please contact:
    Prof. Dr. Uwe A. O. Heinlein
    Corporate Communications, Miltenyi Biotec GmbH
    Friedrich-Ebert-Str. 68, 51429 Bergisch Gladbach, Germany
    Phone +49-2204-8306-6590
    E-mail uweh@miltenyibiotec.de

SOURCE Miltenyi Biotec GmbH

Source: newswire

comments powered by Disqus